SLC5A2 and hydrops fetalis: In addition to these agents, recent evidence suggests that angiotensin receptor neprilysin inhibitor (ARNI) and sodium-glucose cotransporter 2 inhibitor (SGLT2i) are efficacious in terms of improved cardiac function, quality of life, and prognosis of HF, and they have been recognized as the standard medication for HF treatment [5,6].